Posted by Michael Wonder on 14 Jun 2017
Pfizer and Lilly receive FDA fast track designation for tanezumab
13 June 2017 - Global Phase 3 program is studying potential new treatment option for millions of people living with chronic pain associated with osteoarthritis and chronic low back pain.
Pfizer and Eli Lilly today announced that the U.S. FDA has granted fast track designation for tanezumab for the treatment of chronic pain in patients with osteoarthritis and chronic low back pain.
Tanezumab is an investigational humanised monoclonal antibody that selectively targets, binds to and inhibits nerve growth factor (NGF). It is the first NGF inhibitor to receive fast track designation, a process designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs.
